- Home
- AMRX vs ZLAB Comparison
AMRX vs ZLAB Comparison
Compare AMRX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRX
- ZLAB
- Stock Information
- Founded
- AMRX 2002
- ZLAB 2013
- Country
- AMRX United States
- ZLAB China
- Employees
- AMRX N/A
- ZLAB N/A
- Industry
- AMRX Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- AMRX Health Care
- ZLAB Health Care
- Exchange
- AMRX Nasdaq
- ZLAB Nasdaq
- Market Cap
- AMRX 3.3B
- ZLAB 3.2B
- IPO Year
- AMRX N/A
- ZLAB 2017
- Fundamental
- Price
- AMRX $10.21
- ZLAB $26.34
- Analyst Decision
- AMRX Buy
- ZLAB Buy
- Analyst Count
- AMRX 3
- ZLAB 6
- Target Price
- AMRX $12.00
- ZLAB $57.22
- AVG Volume (30 Days)
- AMRX 1.4M
- ZLAB 708.9K
- Earning Date
- AMRX 10-30-2025
- ZLAB 11-06-2025
- Dividend Yield
- AMRX N/A
- ZLAB N/A
- EPS Growth
- AMRX N/A
- ZLAB N/A
- EPS
- AMRX 0.01
- ZLAB N/A
- Revenue
- AMRX $2,852,914,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- AMRX $9.70
- ZLAB $41.80
- Revenue Next Year
- AMRX $6.53
- ZLAB $49.93
- P/E Ratio
- AMRX $970.62
- ZLAB N/A
- Revenue Growth
- AMRX 9.81
- ZLAB 32.56
- 52 Week Low
- AMRX $6.69
- ZLAB $23.82
- 52 Week High
- AMRX $10.68
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- AMRX 52.54
- ZLAB 34.41
- Support Level
- AMRX $10.13
- ZLAB $25.13
- Resistance Level
- AMRX $10.62
- ZLAB $29.77
- Average True Range (ATR)
- AMRX 0.28
- ZLAB 1.01
- MACD
- AMRX -0.01
- ZLAB -0.35
- Stochastic Oscillator
- AMRX 57.02
- ZLAB 17.93
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.